- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00329355
Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)
20. januar 2017 opdateret af: GlaxoSmithKline
A Randomized, Double-blind, Single Migraine Attack, Placebo-controlled, Parallel-group Multicenter Study to Evaluate the Efficacy and Tolerability of Trexima (Sumatriptan Succinate.Naproxen Sodium) Tablets vs Placebo When Administered During the Mild Pain Phase of Menstrual Migraine in Women With Dysmenorrhea
This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
A randomized, double-blind, single migraine attack, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and tolerability of TREXIMA* (sumatriptan succinate/naproxen sodium) tablets vs placebo when administered during the mild pain phase of menstrual migraine in women with dysmenorrhea (*TREXIMET)
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
351
Fase
- Fase 3
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forenede Stater, 85224
- GSK Investigational Site
-
-
California
-
Irvine, California, Forenede Stater, 92618
- GSK Investigational Site
-
Redondo Beach, California, Forenede Stater, 90277
- GSK Investigational Site
-
San Francisco, California, Forenede Stater, 94109
- GSK Investigational Site
-
Santa Monica, California, Forenede Stater, 90404
- GSK Investigational Site
-
-
Colorado
-
Boulder, Colorado, Forenede Stater, 80304
- GSK Investigational Site
-
Colorado Springs, Colorado, Forenede Stater, 80909
- GSK Investigational Site
-
-
Florida
-
Port Orange, Florida, Forenede Stater, 32127
- GSK Investigational Site
-
Sunrise, Florida, Forenede Stater, 33351
- GSK Investigational Site
-
West Palm Beach, Florida, Forenede Stater, 33407
- GSK Investigational Site
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60614
- GSK Investigational Site
-
-
Indiana
-
South Bend, Indiana, Forenede Stater, 46601
- GSK Investigational Site
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70808
- GSK Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48104
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68134
- GSK Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87108
- GSK Investigational Site
-
-
New York
-
New York, New York, Forenede Stater, 10022
- GSK Investigational Site
-
New York, New York, Forenede Stater, 10021
- GSK Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27103
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45245
- GSK Investigational Site
-
Cincinnati, Ohio, Forenede Stater, 45267
- GSK Investigational Site
-
Toledo, Ohio, Forenede Stater, 43614-5809
- GSK Investigational Site
-
West Chester, Ohio, Forenede Stater, 45069
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- GSK Investigational Site
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97210
- GSK Investigational Site
-
-
Pennsylvania
-
Carnegie, Pennsylvania, Forenede Stater, 15106
- GSK Investigational Site
-
Philadelphia, Pennsylvania, Forenede Stater, 19114
- GSK Investigational Site
-
-
Rhode Island
-
Warwick, Rhode Island, Forenede Stater, 02886
- GSK Investigational Site
-
-
South Carolina
-
Mount Pleasant, South Carolina, Forenede Stater, 29464
- GSK Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- GSK Investigational Site
-
-
Texas
-
Georgetown, Texas, Forenede Stater, 78626
- GSK Investigational Site
-
Houston, Texas, Forenede Stater, 77054
- GSK Investigational Site
-
San Antonio, Texas, Forenede Stater, 78229
- GSK Investigational Site
-
-
Utah
-
Salt Lake City, Utah, Forenede Stater, 84109
- GSK Investigational Site
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- GSK Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 65 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Kvinde
Beskrivelse
Inclusion Criteria:
- At least a 6 month history of physician diagnosed migraine and typically experiences 2-6 migraine attacks per month
- Typically experiences moderate to severe migraine pain preceded by a mild pain phase
- Differentiate between mild migraine pain and other headache types
- Women of childbearing potential must be on adequate contraception
Exclusion Criteria:
- Pregnant and/or nursing mother
- History of cardiovascular disease
- Uncontrolled hypertension
- Basilar or Hemiplegic migraine
- History of stroke or transient ischemic attacks (TIA)
- History of epilepsy or treated with anti-epileptics within past 5 years
- Impaired hepatic or renal function
- History of gastrointestinal bleeding or ulceration
- Allergy or hypersensitivity to aspirin or any other NSAID
- Allergy or hypersensitivity to triptans
- Participated in an investigational drug trial in the previous 4 weeks
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Score on a 4-pt migraine pain scale for a single menstrual migraine attack
Tidsramme: 2 to 48 hours
|
2 to 48 hours
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Freedom from all migraine pain and symptoms, satisfaction, presence or absence of neck pain/discomfort, sinus pain/pressure, menstrual symptoms, recurrence of head pain, safety and tolerability
Tidsramme: 2 to 48 hours
|
2 to 48 hours
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Generelle publikationer
- Durham PL, Vause CV, Derosier F, McDonald S, Cady R, Martin V. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache. 2010 May;50(5):844-51. doi: 10.1111/j.1526-4610.2010.01657.x. Epub 2010 Mar 26.
- Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD, Derosier FJ, McDonald SA. Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol. 2009 Jul;114(1):106-113. doi: 10.1097/AOG.0b013e3181a98e4d.
- Martin VT, Ballard J, Diamond MP, Mannix LK, Derosier FJ, Lener SE, Krishen A, McDonald SA. Relief of menstrual symptoms and migraine with a single-tablet formulation of sumatriptan and naproxen sodium. J Womens Health (Larchmt). 2014 May;23(5):389-96. doi: 10.1089/jwh.2013.4577. Epub 2014 Feb 28.
- Cady RK, Diamond ML, Diamond MP, Ballard JE, Lener ME, Dorner DP, Derosier FJ, McDonald SA, White J, Runken MC. Sumatriptan-naproxen sodium for menstrual migraine and dysmenorrhea: satisfaction, productivity, and functional disability outcomes. Headache. 2011 May;51(5):664-73. doi: 10.1111/j.1526-4610.2011.01894.x.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. maj 2006
Primær færdiggørelse (Faktiske)
1. november 2006
Studieafslutning (Faktiske)
1. november 2006
Datoer for studieregistrering
Først indsendt
22. maj 2006
Først indsendt, der opfyldte QC-kriterier
23. maj 2006
Først opslået (Skøn)
24. maj 2006
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
23. januar 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
20. januar 2017
Sidst verificeret
1. januar 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Hovedpinelidelser, Primær
- Hovedpine lidelser
- Migræne lidelser
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Agenter fra det perifere nervesystem
- Enzymhæmmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirheumatiske midler
- Cyclooxygenase-hæmmere
- Serotoninmidler
- Serotonin 5-HT1-receptoragonister
- Serotoninreceptoragonister
- Gigthæmmende midler
- Vasokonstriktormidler
- Naproxen
- Sumatriptan
Andre undersøgelses-id-numre
- TRX105852
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokumenter
-
Annoteret sagsbetænkningsformular
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokol
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk undersøgelsesrapport
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Individuelt deltagerdatasæt
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Formular til informeret samtykke
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datasætspecifikation
Informations-id: TRX105852Oplysningskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med sumatriptan succinat/naproxen natrium
-
NuPathe Inc.Afsluttet
-
GlaxoSmithKlineAfsluttet
-
NuPathe Inc.AfsluttetSammenlign bioækvivalensplastre, der tidligere er brugt i NP101-007-undersøgelsenForenede Stater
-
Sorrento Therapeutics, Inc.Kimberly-Clark CorporationAfsluttetMigræne lidelserForenede Stater
-
PfizerAfsluttet
-
Teva Pharmaceuticals USAAfsluttet
-
Dr. Reddy's Laboratories LimitedAfsluttetHurtigt eskalerende migræneForenede Stater
-
Teva Pharmaceuticals USAAfsluttet
-
NuPathe Inc.Afsluttet
-
Charleston Laboratories, IncAfsluttetSmerte | Kvalme | Opkastning | Migræne | AuraForenede Stater